词条 | North China Pharmaceutical Group |
释义 |
OrganizationNCPC now has 29 subsidiaries. Among which North China Pharmaceutical Co., Ltd. is a listed company at Shanghai Stock Exchange with 59.87% of shares held by NCPC. NCPC is one of the four groups of the candidate enterprises approved by China Securities Regulatory Commission for overseas listing. Keeping in close cooperation with foreign companies and institutions, NCPC has established 16 joint ventures and cooperative ventures. ProductsNCPC currently produces over 430 kinds of antibiotics, semi-synthetic antibiotics, pharmaceutical intermediates, synthetic vitamins, biotechnology products, veterinary and neutraceuticals both in bulk and in finished products. NCPC sells bulk antibiotics {{convert|7000|t}}, vitamins 10000 tons, antibiotic intermediates 7500 tons, powder for injection 1.8 billion vials, capsules 1.03 billion grains annually. The capacity of penicillin, streptomycin, 6-APA, amoxycillin, cefaradine, vitamin B100 are in the lead worldwide. NCPC's next development focus is on biotechnology products, bio-pesticides and animal products. Since 1984, NCPC has initiated research on modern biotechnology and formed the system for developing generic drug involving new products R&D, pilot production and commercial production. In cooperation with the foreign companies, NCPC has completed the design and construction of GeneTech Biotechnology Co., Ltd. who is now a modern biotechnology production base in line with international practice and standards. There are rhGM-CSF, rhG-CSF, EPO and Hepatitis B Vaccine (CHO) on market at present. R&DThrough its independent research and development, NCPC was the first in China to succeed in developing dozen of new products: such as bacitracin, kasugamycin, bleomycin, amphotericin B, lindomycin, clindamycin, clindamycin phosphate and norvancomycin. NCPC New Drug R&D Co., Ltd. is responsible for the new drug and technology development of the whole NCPC Group. Nearly 300 experts and technicians, advanced instruments and integrated pilot unit make it possible to transform laboratory reactions into large-scale production. In recent 10 years, R&D investment of NCPC kept occupying over 30% of sales volume annually. NCPC has been transferring from generic imitation into original research in new drug development and forming a development platform of its own. Its original research focuses on the natural and small molecular drugs screening, combinatorial chemical technology and modern biotechnology. See also
References1. ^North China Pharmaceutical Group Corp External links
9 : Pharmaceutical companies of China|Companies based in Hebei|1958 establishments in China|Vaccine producers|Generic drug manufacturers|Biotechnology companies|Biotechnology companies of China|Chinese brands|Pharmaceutical companies established in 1958 |
随便看 |
|
开放百科全书收录14589846条英语、德语、日语等多语种百科知识,基本涵盖了大多数领域的百科知识,是一部内容自由、开放的电子版国际百科全书。